Immunocore Holdings plc
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
IMCR$32.38+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, and
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $467,709 | $455,731 |
| Marketable securities | 396,444 | 364,645 |
| Accounts receivable, net | 73,977 | 63,009 |
| Prepaid expenses and other current assets | 50,055 | 41,033 |
| Tax receivable | 1,815 | — |
| Inventory, net | 6,742 | 5,446 |
| Total current assets | 996,742 | 929,864 |
| Property and equipment, net | 11,462 | 10,092 |
| Operating lease right of use assets, net | 38,783 | 37,643 |
| Deferred tax assets, net | — | 14,790 |
| Other non-current assets | 20,282 | 17,117 |
| Total assets | $1,067,269 | $1,009,506 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $24,364 | $25,100 |
| Accrued expenses and other current liabilities | 219,744 | 185,534 |
| Deferred revenue, current | 583 | — |
| Operating lease liabilities, current | 2,006 | 1,547 |
| Total current liabilities | 246,697 | 212,181 |
| Deferred revenue, non-current | 4,858 | 5,434 |
| Operating lease liabilities, non-current | 41,556 | 40,162 |
| Interest-bearing loans and borrowings | 393,125 | 391,013 |
| Total liabilities | 686,236 | 648,790 |
| Commitments and contingencies (Note 14) | ||
| Shareholders’ equity | ||
| Ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £149,633 and £97,454 shares as of December 31, 2025 and 2024, respectively, and 50,689,271 and 50,064,860 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | 136 | 135 |
| Deferred shares, £0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of December 31, 2025 and 2024. | 1 | 1 |
| Additional paid-in capital | 1,240,255 | 1,190,104 |
| Accumulated deficit | (831,275) | (795,761) |
| Accumulated other comprehensive loss | (28,084) | (33,763) |
| Total shareholders’ equity | 381,033 | 360,716 |
| Total liabilities and shareholders’ equity | $1,067,269 | $1,009,506 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.